The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity

被引：4
|
作者：
Godwin, Colin D. [1 ,2 ]
Bates, Olivia M. [1 ]
Garling, Eliotte E. [1 ]
Beddoe, Mary E. [1 ]
Laszlo, George S. [1 ]
Walter, Roland B. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98195 USA
[2] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 01期
基金：
美国国家卫生研究院;
关键词：
acute leukaemia; bispecific antibody; Bruton's tyrosine kinase; ibrutinib; IL-2-inducible T-cell kinase;
D O I：
10.1111/bjh.16406
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E9 / +
页数：5
相关论文
共 50 条
  • [31] ENHANCED ANTIBODY-MEDIATED PHAGOCYTOSIS AND ANTIBODY-MEDIATED CELL CYTOTOXICITY USING TETRAVALENT, BISPECIFIC INNATE CELL ENGAGERS (ICE®) IN 3D SPHEROIDS
    Pinto, Sheena
    Jackson, Savannah
    Knoch, Julia
    Breunig, Christian
    Schottelius, Arndt
    Koch, Joachim
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A923 - A923
  • [32] Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia
    Barrientos, Jacqueline
    Rai, Kanti
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1817 - 1820
  • [33] Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia
    Hosier, Gregory W.
    Touma, Naji J.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (05): : E237 - E239
  • [34] Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
    Anna Turetsky
    Eunha Kim
    Rainer H. Kohler
    Miles A. Miller
    Ralph Weissleder
    Scientific Reports, 4
  • [35] Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
    Turetsky, Anna
    Kim, Eunha
    Kohler, Rainer H.
    Miller, Miles A.
    Weissleder, Ralph
    SCIENTIFIC REPORTS, 2014, 4
  • [36] The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma
    Fowler, Nathan H.
    Advani, Ranjana H.
    Sharman, Jeff
    Smith, Sonali M.
    McGreivy, Jesse
    Kunkel, Lori
    Vina Troung
    Zhou, Cathy
    Boyd, Thomas E.
    BLOOD, 2012, 120 (21)
  • [37] Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenstrom's macroglobulinemia
    Furman, Richard R.
    Luan, Ying
    Bilotti, Elizabeth
    Graef, Thorsten
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1502 - 1505
  • [38] A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia
    Treon, Steven Peter
    Tripsas, Christina K.
    Yang, Guang
    Cao, Yang
    Xu, Lian
    Hunter, Zachary
    Cropper, Steven J.
    Mostyn, Patrick
    Meid, Kirsten
    Warren, Diane
    Patterson, Christopher
    Varma, Gaurav
    Laubach, Jacob P.
    Paba-Prada, Claudia E.
    Kunsman, Janet
    Ghobrial, Irene M.
    Kanan, Sandra
    Advani, Ranjana H.
    Palomba, Maria Lia
    BLOOD, 2013, 122 (21)
  • [39] Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
    Neeraj Jain
    Mukesh Mamgain
    Sayan Mullick Chowdhury
    Udita Jindal
    Isha Sharma
    Lalit Sehgal
    Narendranath Epperla
    Journal of Hematology & Oncology, 16
  • [40] Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem- like traits in ovarian cancer
    Zucha, Muhammad Ary
    Wu, Alexander T. H.
    Lee, Wei-Hwa
    Wang, Liang-Shun
    Lin, Wan-Wan
    Yuan, Chiou-Chung
    Yeh, Chi-Tai
    ONCOTARGET, 2015, 6 (15) : 13255 - 13268
12345